Trajan Group Holdings Ltd · ASX:TRJ
Trajan — FY2022 Earnings Presentation
18 slides from Trajan's earnings presentation, Aug 24, 2022
Slide 1: FY22 Financial Results
For personal use only FY22 FINANCIAL RESULTS Stephen Tomisich CEO and Managing Director 24th August 2022 1 Science that benefits people
Slide 2: Our vision is becoming a reality
For personal use only Respect Our vision is becoming a reality. In FY22 we transformed to a new scale, Integrity expanded our customer sets, drove new technology adoption, delivered on all Discipline financial metrics, and there is more to come. Empowerment Science Sciencethat thatbenefits benefitsp
Slide 3: Financial Highlights
Financial Highlights Science that benefits people Strong sales and profit growth across the group For personal use only Total Revenue $107.6M • Revenue of $22.7M and $2.1M of EBITDA added 40.5%1 from new acquisitions. • Organic revenue growth of 10.8%1. Normalised EBITDA • Revenue growth of 15.0%1 i
Slide 4: Momentum Building to Global Scale
Momentum Building to Global Scale Science that benefits people For personal use only FY 22 key operational highlights: • Acquired Axel Semrau, Neoteryx, LEAP PAL Parts and Consumables, and Chromatography Research Supplies. 11 661 Acquisitions Employees • Invested in Forth With Life to progress Traja
Slide 5: Despite Global Turmoil Trajan Delivers to Plan
Despite Global Turmoil Trajan Delivers to Plan Science that benefits people Consistent performance in line with guidance For personal use only Actual IPO Prospectus (excluding acquisitions) $M $M • Resilience and strength of Trajan’s diverse FY21 Revenue 74.6 76.6 business and mitigation actions hav
Slide 6: FY23 Outlook
FY23 Outlook Science that benefits people In just one year Trajan has changed scale For personal use only $21.0M Trajan’s business (Revenue and $150.0M to EBITDA) is running at double to $160.0M Expected Revenue $25.0M the rate of its IPO starting point range Expected Normalised EBITDA range just ov
Slide 7: FY2022 Financial Snapshot
FY2022 Financial Snapshot Science that benefits people Strong order demand and growth continues across the Trajan businesses For personal use only Revenue ($m) & Gross Profit Margin^ % Normalised EBITDA ($m) & Normalised* EBITDA Margin % Trajan recorded overall revenues for the year ended 30 June 20
Slide 8: FY2022 Segment breakdown
FY2022 Segment breakdown Science that benefits people Successful acquisitions elevate underlying business portfolio and extend growth opportunities For personal use only Analytical Products Life Science Solutions • Revenue grew by $7.9M (up by 15.0% over pcp) and gross profit^ grew by $3.2M (up by •
Slide 9: FY22 Operational Update
Science that benefits people For personal use only FY22 Operational Update Science that benefits people
Slide 10: Our International Presence Aligning with our Major Markets
Our International Presence Aligning with our Major Markets Science that benefits people Increasingly global; 55% of staff now outside of Australia For personal use only Global Headcount 700 8, Japan 7, Other 54, 18, UK 600 Germany 298, 500 Australia 400 128, 300 Malaysia 200 100 148, USA 0 June 2021
Slide 11: Four Acquisitions Completed in Year
Four Acquisitions Completed in Year 1 Science that benefits people All tracking to, or beyond, plan For personal use only • Record order book, (remains high), new warehouse site purchased, Trajan Japan and Malaysia integration underpinning expansion. • What a start! • Now global microsampling hub, c
Slide 12: Continuing to Build and Improve: Operations
Continuing to Build and Improve Science that benefits people For personal use only Operations • Project Neptune starting to deliver gains. Production automation and Malaysian transfers progressing. • Senior regulatory resource appointed in the USA. • Bethel CT business emerges with 21% growth, lever
Slide 13: Continuing to Build and Improve: New technologies
Continuing to Build and Improve Science that benefits people For personal use only New technologies • Hummingbird™ miniaturised HPLC successful trials in pharmaceutical and environmental applications. • uLLE™ characterisation work and product refinement progress. Continued to work with beta test sit
Slide 14: Vision to Reality; Microsampling Accelerating
Vision to Reality; Microsampling Accelerating Science that benefits people The pandemic changed the paradigm For personal use only • Order rate accelerating into FY23. • Neoteryx team now securing hemaPEN® sales. • Trajan devices supporting more than a dozen pharmaceutical drug trials. • Proposals o
Slide 15: Vision to Reality; Personalised, Preventative Healthcare
Vision to Reality; Personalised, Preventative Healthcare Science that benefits people The Baker Heart and Diabetes Institute and cardiovascular risk assessment For personal use only • Trajan and The Baker Heart and Diabetes Institute have been working together since 2019 on an AI tool to assess card
Slide 16: Vision to Reality; MonitorYou Launching
Vision to Reality; “MonitorYou” Launching Science that benefits people Personalised preventative data-based healthcare For personal use only • To drive adoption of microsampling tools and decentralised measurement. • Starting with “healthy heart” program. • https://monitoryou.com/ • Progressing towa
Slide 17: Q&A
17 Science that benefits people For personal use only Q&A Science that benefits people
Slide 18: Disclaimer
Disclaimer Science that benefits people For personal use only The material in this presentation is general background information about Trajan Group Holdings Limited (Trajan) and is current at the date of the presentation, 24 August 2022. The information in the presentation is provided for informati